ADR Biomedical Holdings Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ADR Biomedical Holdings Inc.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 98% of Healthcare companies in Japan.
- Tangible Assets Ratio: Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in Japan.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 2 of 3. Less steady than 90% of Healthcare companies in Japan.
Where ¥100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 90% of Healthcare companies in Japan.
Growth Efficiency Ratio
—Sales fell 98%
Sales fell 98% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-98% / -97%In 3 years sales changed by -98% while total assets changed by -97%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 54% of Healthcare companies in Japan.
Tangible Assets Ratio
100%Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in Japan.
Tangible Net Worth Ratio
100%Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 98% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
ADR Biomedical Holdings Inc. made a loss over the last year. ADR Biomedical Holdings Inc. owes ¥1.20 for every ¥1 it owns. ADR Biomedical Holdings Inc. made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
LossADR Biomedical Holdings Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-97.64ADR Biomedical Holdings Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
¥7.0 BThe total market value of all of ADR Biomedical Holdings Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeADR Biomedical Holdings Inc.'s net worth is negative (¥72 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-267.6%ADR Biomedical Holdings Inc. lost 267.6% of its shareholders' money over the last year, lower than 98% of Healthcare companies in Japan.
Owes vs Owns
1.20×ADR Biomedical Holdings Inc. owes ¥1.20 for every ¥1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in Japan.
Dividend yield
NoneADR Biomedical Holdings Inc. does not currently pay a dividend.
Revenue growth
-58%Revenue fell 58% in the year to Mar 2026, and shrank 71% a year on average over 3 years.
Profit growth
LossADR Biomedical Holdings Inc. made a loss in each of the last two years.
Profit margin
-778.4%ADR Biomedical Holdings Inc. lost ¥778 for every ¥100 of revenue.
Interest cover
Not coveredADR Biomedical Holdings Inc.'s operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net cashADR Biomedical Holdings Inc. held ¥126 M more cash than debt (net cash) at Mar 2026.
Questions
What is ADR Biomedical Holdings Inc.'s return on equity?
ADR Biomedical Holdings Inc. lost 267.6% of its shareholders' money over the last year, lower than 98% of Healthcare companies in Japan.
How much does ADR Biomedical Holdings Inc. owe compared with what it owns?
ADR Biomedical Holdings Inc. owes ¥1.20 for every ¥1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in Japan.
Does ADR Biomedical Holdings Inc. pay a dividend?
No. ADR Biomedical Holdings Inc. does not currently pay a dividend.
Is ADR Biomedical Holdings Inc.'s revenue growing?
Revenue fell 58% in the year to Mar 2026, and shrank 71% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.